FDA Approves Genentech's Enspryng, a First-in-Class IL-6R Inhibitor, as First, Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease
October 17, 2026
October 17, 2026
SOUTH SAN FRANCISCO, California, Oct. 17 -- Genentech, a member of the Roche Group, issued the following news release:
* * *
FDA Approves Genentech's Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (d . . .
* * *
FDA Approves Genentech's Enspryng, a First-in-Class IL-6R Inhibitor, as the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
FDA approval based on Phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (d . . .